DAMORA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
DAMORA THERAPEUTICS, INC. (DMRA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $24.29 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $24.16, a 323.86% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.70.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.22, a 60.52% decline year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $7.04, a 8.69% decline from fiscal 2024.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $7.71, a 75.92% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $32.02, a 974.50% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.98, a 68.60% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $24.29 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | $24.16 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $7.04 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $5.38 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $5.38 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $5.70 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | $7.71 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $12.25 10-Q · filed 2024-11-01 | ||||
| 2024-06-30 | $0.49 10-Q · filed 2024-08-12 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2024-04-29 | ||||
| 2023-12-31 | $32.02 10-K · filed 2025-03-19 | $1.28 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $1.28 10-Q · filed 2023-11-06 | ||||
| 2023-06-30 | $1.28 10-Q · filed 2023-07-31 | ||||
| 2023-03-31 | $1.22 10-Q · filed 2023-04-28 | ||||
| 2022-12-31 | $2.98 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | $2.98 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $3.01 10-Q · filed 2022-07-29 | ||||
| 2022-03-31 | $3.09 10-Q · filed 2022-04-29 | ||||
| 2021-12-31 | $9.49 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $9.79 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $10.40 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | $12.89 10-Q · filed 2021-05-04 | ||||
| 2020-12-31 | $4.67 10-K · filed 2022-02-17 | ||||
| 2020-09-30 | $1.95 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |